Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effect of Doxycycline in Patients With Amyloidosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older~* Biopsy-proven amyloidosis~* Biochemical or clinical evidence of amyloid induced end-organ dysfunction~Exclusion Criteria:~* Concurrent use of other tetracyclines~* Ongoing active treatment for amyloidosis~* Pregnancy or unwillingness to use contraception by women of childbearing age~* Doxycycline drug allergy/hypersensitivity~* ECOG performance status \> 3~* NYHA class \> 3~* Renal insufficiency (estimated creatinine clearance \< 25 ml/min)~* Transaminitis (AST or ALT \> 5 times upper limit of normal)~* Diabetes mellitus or hemoglobin A1C \> 6.2%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- doxycycline 100 mg po bid x 12 months (Type: EXPERIMENTAL): Open-label doxycycline 100 mg twice daily by mouth will be administered to subjects for 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).